Abstract: Objective To explore the correlation between Farnesoid X Receptor (FXR) and clinical stage and survival time of patients with pancreatic cancer. Methods The total protein and mRNA were extracted from cultured 8 pancreatic cancer cell lines, and the expression level of FXR in pancreatic cancer cells was detected by Western Bolt and Real-Time PCR. We Collected 5 cases of normal pancreatic tissue and 50 cases of pancreatic cancer tissues, and used immunohistochemistry method to detect FRX expression in normal pancreatic tissue and pancreatic cancer. According to the different expression level of FXR, these 50 patients were divided into low expression group and high expression group, and the correlation of clinical data and FRX expression level was analyzed. Furthermore, Kaplan-Meier and log-rank analysis of prognostic factors was assessed in a multivariable analysis using a Cox proportional hazards model. Results FXR was differently expressed in 8 pancreatic cancer cell lines and pancreatic cancer tissues. FXR was closely related to the pathological G stage of pancreatic cancer (P<0.05). FXR and pathological G stage were significantly correlated with the patients’ survival time. The survival time of the patients with high FXR expression was significantly longer than that of patients with low FXR expression (P<0.05). Conclusions The expression of FXR is closely related to the pathological G stage in patients with pancreatic cancer. Both FXR expression and pathological G stage are independent prognostic factors in patients with pancreatic cancer.

Key words: Pancreatic cancer, Immunohistochemistry, Farnesoid X Receptor（FXR）